Biotech · Public company · Seattle, WA, US
Omeros Corp
Ticker OMER · SEC CIK 0001285819
Track this companyFree. Adds Omeros Corp to your Dealase workspace and tells you when its record changes.
Clinical trials71 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline7
- OMS302Phase 3 · Unilateral Cataract ExtractionClinicalTrials.gov · fetched Nov 12, 2026
- OMS721Phase 3 · IgA NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- OMS721 (narsoplimab)Phase 3 · Thrombotic MicroangiopathiesClinicalTrials.gov · fetched Nov 12, 2026
- Phenylephrine HClPhase 3 · Unilateral Cataract ExtractionClinicalTrials.gov · fetched Nov 12, 2026
- Biological: narsoplimabPhase 2 · Thrombotic MicroangiopathiesClinicalTrials.gov · fetched Nov 12, 2026
- OMS721Phase 2 · Thrombotic MicroangiopathiesClinicalTrials.gov · fetched Nov 12, 2026
- OMS721 (narsoplimab)Phase 2 · IgANClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMAPHASE2 · RECRUITING · started May 1, 2023ClinicalTrials.gov NCT05855083 · fetched Nov 12, 2026
- No Drop Post-Op Cataract SurgeryPHASE4 · COMPLETED · started Jul 8, 2019ClinicalTrials.gov NCT03864133 · fetched Nov 12, 2026
- Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic SyndromePHASE3 · TERMINATED · started May 2, 2018ClinicalTrials.gov NCT03205995 · fetched Nov 12, 2026
- Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) NephropathyPHASE3 · TERMINATED · started Apr 5, 2018ClinicalTrials.gov NCT03608033 · fetched Nov 12, 2026
- Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721PHASE2 · TERMINATED · started Mar 10, 2016ClinicalTrials.gov NCT02682407 · fetched Nov 12, 2026
- Safety and Efficacy Study of OMS721 in Patients With Thrombotic MicroangiopathiesPHASE2 · COMPLETED · started Nov 2, 2014ClinicalTrials.gov NCT02222545 · fetched Nov 12, 2026
- A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens ReplacementPHASE3 · COMPLETED · started Jul 1, 2014ClinicalTrials.gov NCT02132312 · fetched Nov 12, 2026
SEC filings12
- 8-KSEC EDGAR · filed Oct 30, 2026 · fetched Nov 12, 2026
- 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jul 20, 2026 · fetched Nov 12, 2026
- 8-KSEC EDGAR · filed Jul 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 25, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 18, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
- 10-K · FORM 10-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
NIH awards2
- PDE7 Inhibitor for the Treatment of Cocaine Use DisorderFiscal year 2025 · $4.5MNIH RePORTER 5U01DA058541-03 · fetched Nov 12, 2026
- PDE7 Inhibitor for the Treatment of Cocaine Use DisorderFiscal year 2024 · $845.3KNIH RePORTER 5U01DA058541-02 · fetched Nov 12, 2026